
Research Trends of Tyrosine Kinase Inhibitors in EGFR-Mutated Non-Small Cell Lung Cancer: A Bibliometric Analysis
Background Non-small cell lung cancer (NSCLC) is the predominant form of lung cancer, representing approximately 85% of all lung cancer cases globally.1 Among the various genetic alterations in NSCLC, mutations in the epidermal growth factor receptor (EGFR …